Effect of LANCONONE in Weight-bearing Joint Pain

To Assess the Lanconone® (E-OA-07) Efficacy in Weight-bearing Joint Pain

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03658369

Enrollment

Registered

2018-09-05

Start date

2018-08-16

Completion date

2019-05-15

Last updated

2019-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteo Arthritis Knee

Brief summary

The current study has been designed to primarily assess the effect of Lanconone® in comparison to placebo on pain in weight bearing joints.

Interventions

DIETARY_SUPPLEMENTLanconone®

2 capsules

DIETARY_SUPPLEMENTMethyl crystalline cellulose

2 Capsules

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

40 Years to 65 Years

Healthy volunteers

Inclusion criteria

1. BMI ≥ 25 and ≤ 29.9 kg/m2. 2. With unilateral or bilateral OA of the knee for at least greater than 3 months, as presented by pain in the knee at least for last 3 months. 3. Post-menopausal females (LMP at least 12 months prior to the screening).

Exclusion criteria

1. History of osteoarthritis for more than 3 years. 2. Systolic Blood Pressure ≥140 mm Hg and Diastolic Blood Pressure ≥ 90 mm Hg 3. FBS\>140 mg/dl. 4. Smokers or chronic alcoholics. 5. Participants planning to travel in the next 56 days or engage in any non-routine activity that is likely to strain the knees.

Design outcomes

Primary

Measure	Time frame	Description
WOMAC (Western Ontario and McMaster universities Osteoarthritis Index) pain score	56 days	Change in pain score.The score ranges from 0-5, wherein 0 indicates no pain and 5 indicates extreme pain.

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026